CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishPaclitaxel has been approved as second-line therapy after anthracyclines in AIDS-Kaposi's sarcoma (KS) patients. To date, only one patient with classical KS and treated with standard dose (175 mg/m2) 3-weekly paclitaxel as first line therapy has been reported in the literature. Herein, the first case is presented of a patient with anthracycline-refractory classical KS who was treated with standard dose 3-weekly and paclitaxel after five cycles of therapy achieved a partial response according to the AIDS Clinical Trials Group criteria.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Titolo: | Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma | |
| Autori: | ||
| Data di pubblicazione: | 2009 | |
| Rivista: | ||
| Abstract: | Paclitaxel has been approved as second-line therapy after anthracyclines in AIDS-Kaposi's sarcoma (KS) patients. To date, only one patient with classical KS and treated with standard dose (175 mg/m2) 3-weekly paclitaxel as first line therapy has been reported in the literature. Herein, the first case is presented of a patient with anthracycline-refractory classical KS who was treated with standard dose 3-weekly and paclitaxel after five cycles of therapy achieved a partial response according to the AIDS Clinical Trials Group criteria. | |
| Handle: | http://hdl.handle.net/11586/250898 | |
| Appare nelle tipologie: | 1.1 Articolo in rivista |
File in questo prodotto:
Copyright © 2021